

BeiGene Presentations at 2025 ASCO Annual Meeting

Hematology		
BRUKINSA		
SEQUOIA 5-year follow-up of Arm C: Frontline zanubrutinib monotherapy in del(17p) patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma	Rapid Oral Presentation: 7011 Session Title: Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia Session Date/Time: May 31, 2025, 8:00-9:30 AM	C.S. Tam
Combination of zanubrutinib + venetoclax for treatment-naïve CLL/SLL: Results from SEQUOIA Arm D	Rapid Oral Presentation: 7009 Session Title: Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia Session Date/Time: May 31, 2025, 8:00-9:30 AM	M. Shadman
Solid Tumor		
TEVIMBRA		
Tislelizumab (BGB-A317) plus chemotherapy/chemoradiotherapy as positron emission tomography-guided neoadjuvant treatment for resectable esophageal squamous cell carcinoma: RATIONALE-213 final analysis	Poster #: 317 Poster Presentation Session Title: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Session Date/Time: May 31, 2025, 9:00 AM-12:00 PM	L. Chen
Final analysis of multicenter, open-label, phase 2 study evaluating the efficacy and safety of tislelizumab in combination with fruquintinib in patients with selected solid tumors	Poster #: 251 Poster Presentation Session Title: Developmental Therapeutics – Immunotherapy Session Date/Time: June 2, 2025, 1:30 PM-4:30 PM	K. Lee
Pipeline		
BG-68501 (CDK2i)		

A first-in-human, phase 1a/b, dose-escalation/expansion study of BG-68501, a selective CDK2 inhibitor, as monotherapy or in combination with fulvestrant for patients with HR+/HER2- breast cancer and other advanced solid tumors: First disclosure of clinical data	Poster#: 430 Poster Presentation Session Title: Development Therapeutics - Molecularly Targeted Agents and Tumor Biology Session Date/Time: June 2, 2025, 1:30-4:30 PM	R. Joshi
BG-C9074		
First-in-human study of BG-C9074, a B7-H4-targeting ADC in patients with advanced solid tumors: Preliminary results of the dose-escalation phase	Poster #: 348 Poster Presentation Session Title: Development Therapeutics - Molecularly Targeted Agents and Tumor Biology Session Date/Time: June 2, 2025, 1:30-4:30 PM	C.A. Perez
BGB-A445 (OX40)		
A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced NSCLC, HNSCC or NPC	Poster #: 172 Poster Presentation Session Title: Development Therapeutics - Molecularly Targeted Agents and Tumor Biology Session Date/Time: June 2, 2025, 1:30-4:30 PM	M. Hee Hong
A phase 2 study of the OX40 agonist BGB-A445, in combination with docetaxel or BGB-15025, an HPK1 inhibitor, in patients with NSCLC pretreated by anti-PD-(L)1 antibodies	Abstract #: e14513 Online Abstract	T. Min Kim
Additional Abstracts		
Clinical Trial Diversity		

Lung cancer enrollment of demographic subgroups in US clinical trial sites	Poster #: 216 Poster Presentation Session Title: Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Session Date/Time: May 31, 2025, 1:30-4:30 PM	C. Nigoghossian
Integrative Evidence Generation and Health Economics Related to Zanubrutinib		
Preference Survey		
Treatment preferences of patients, caregivers, and physicians in follicular lymphoma: A global discrete-choice experiment study	Poster #: 448 Poster Presentation Session Title: Quality Care/Health Services Research Session Date/Time: May 31, 2025, 1:30-4:30 PM	M. Smith
Matching-Adjusted Indirect Comparison		
Adverse events of interest of zanubrutinib vs. fixed-duration combination of venetoclax and obinutuzumab in treatment-naïve chronic lymphocytic leukemia	Abstract #: e19028 Online Abstract	W. Aldairy
Efficacy of continuous zanubrutinib vs. fixed duration venetoclax in combination with obinutuzumab in treatment-naïve chronic lymphocytic leukemia: A matching-adjusted indirect comparison	Abstract #: e19027 Online Abstract	T. Munir
Comparative efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: A matching-adjusted indirect comparison	Abstract #: e91032 Online Abstract	T. Munir
Network Meta-Analysis		
A network meta-analysis of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve chronic lymphocytic leukemia	Abstract #: e19031 Online Abstract	M. Shadman
Real-World Evidence		

Real-world comparative effectiveness of first-line Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia	Abstract #: e23264 Online Abstract	R. Jacobs
Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia	Abstract #: e13741 Online Abstract	A.S. Kittai
Real-world Bruton tyrosine kinase inhibitor use and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	Abstract #: e23271 Online Abstract	J. Hou
Real-world zanubrutinib treatment patterns in chronic lymphocytic leukemia/small lymphocytic lymphoma among US community oncology patients with prior acalabrutinib therapy	Abstract #: e23265 Online Abstract	J. Hou
Real-world zanubrutinib treatment patterns in mantle cell lymphoma among US community oncology patients with prior Bruton tyrosine kinase inhibitor therapy	Abstract #: e23270 Online Abstract	R. Choksi
Risk of hypertension in patients newly diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma and treated with covalent Bruton tyrosine kinase inhibitors: A real-world study	Abstract #: e23334 Online Abstract	A.K. Ali
Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia: Age-related disparity	Abstract #: e19033 Online Abstract	K. Yang
Serious infections in patients with CLL/SLL treated with combination venetoclax and obinutuzumab compared to those treated with zanubrutinib: A real-world study	Abstract #: e19026 Online Abstract	J. Colasurdo
Comparing real-world treatment patterns and outcomes of zanubrutinib and acalabrutinib in CLL/SLL at University of California academic health centers	Abstract #: e23263 Online Abstract	A. Ayati

For additional information about our presence at the 2025 ASCO Annual Meeting, please visit our meeting hub: congress.beonemedicines.com.